GSK bets US$1B on SiranBio’s ALK7 siRNA to disrupt the obesity market

UK—GSK has entered into an exclusive licensing agreement with China-based SiranBio to secure global rights to its metabolic oligonucleotide therapy SA030 in a deal valued at up to US$1 billion.

The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.

Under the terms, GSK will make an upfront payment and could pay up to US$1.005bn in milestone payments depending on development, regulatory, and commercial progress.

In addition, SiranBio will receive tiered royalties on future global net sales if the therapy reaches the market.

Mechanism and therapeutic rationale

SA030 is a long-acting small interfering RNA (siRNA) therapy designed to target activin receptor-like kinase 7 (ALK7).

The candidate aims to reduce abdominal fat accumulation while preserving lean muscle mass, a feature that could address limitations associated with GLP-1 receptor agonists.

According to SiranBio, the mechanism may lower cardiometabolic risk by influencing fat distribution rather than relying solely on appetite suppression.

The approach also reflects growing industry interest in RNA-based platforms for metabolic diseases.

Competitive ALK7 pipeline developments

Within the same therapeutic space, Arrowhead Pharmaceuticals is advancing its own ALK7-targeting RNA interference candidate, ARO-ALK7.

Early clinical data from a Phase I/IIa study, including combination use with Eli Lilly’s tirzepatide, have shown encouraging metabolic effects, intensifying competition around next-generation obesity targets beyond incretin biology.

GSK metabolic strategy expansion

GSK continues to expand its metabolic disease pipeline as it seeks alternatives to the crowded GLP-1 receptor agonist market.

The company has emphasized therapies that address downstream complications of obesity, including liver and cardiometabolic dysfunction.

Its investigational MASH candidate efimosfermin alfa is currently in the Phase III ZENITH programme, which evaluates efficacy and safety across multiple patient populations.

Additionally, GSK has strengthened its metabolic portfolio through the acquisition of 35Pharma for US$950 million, gaining access to HS235, a pulmonary hypertension asset with potential metabolic benefits linked to fat reduction.

Pipeline updates and market dynamics

In a recent company update, GSK highlighted continued progress in advancing its metabolic research platforms and integrating acquired assets into late-stage development workflows, while maintaining focus on cardiometabolic indications.

The broader obesity treatment market continues to expand rapidly, with analysts projecting global sales to reach US$206 billion in 2031.

As competition intensifies, industry participants are increasingly evaluating non-GLP-1 approaches, including calcitonin receptor-targeting therapies, as potential contributors to future market share.

RNA therapeutics and future development trends

Regulatory agencies continue to prioritize RNA-based therapeutics for metabolic diseases, as improved delivery technologies enhance tissue targeting and safety profiles.

Meanwhile, pharmaceutical companies are accelerating partnerships to diversify obesity pipelines beyond incretin-based drugs.

Investors are closely monitoring early-stage siRNA programs for durability of response and potential muscle-sparing effects.

At the same time, clinical trial expansion in North America, Europe, and Asia is expected to support broader patient recruitment and faster data readouts across cardiometabolic studies in coming years globally.